Patients with scalp, nail, or genital but not palmo-plantar or face/neck psoriasis had significantly higher odds of achieving clearance at week 12 in the anti-IL-17A cohort compared to the other biologics cohort. This evidence concerns the gene IL17A and psoriasis.